Key terms
About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MRNA news
May 13
4:12pm ET
Moderna initiated with an In Line at Evercore ISI
May 13
3:58pm ET
Novavax (NASDAQ:NVAX) Explodes Upward 50% After Sanofi Deal
May 13
9:55am ET
Early notable gainers among liquid option names on May 13th
May 10
7:46am ET
Moderna says FDA does not expect to complete mRNA-1345 BLA review by May 12
May 09
12:30pm ET
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and ACELYRIN, INC. (SLRN)
May 09
12:20pm ET
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), ACELYRIN, INC. (SLRN) and Moderna (MRNA)
May 09
12:01pm ET
Moderna price target raised to $85 from $70 at Deutsche Bank
May 09
7:59am ET
Moderna (MRNA) Receives a Buy from Jefferies
May 06
1:55am ET
Maintaining Hold on Moderna: Balancing Strong Q1 Sales with Future Uncertainties and Pipeline Progress
May 03
9:46am ET
Moderna price target raised to $135 from $125 at RBC Capital
May 03
9:28am ET
Moderna price target raised to $155 from $125 at Jefferies
May 03
8:45am ET
Moderna price target raised to $106 from $91 at Canaccord
May 03
8:32am ET
Moderna price target raised to $163 from $142 at Oppenheimer
May 03
8:23am ET
Analysts Are Bullish on These Healthcare Stocks: Elevation Oncology (ELEV), Moderna (MRNA)
May 03
7:04am ET
RBC Capital Remains a Buy on Moderna (MRNA)
May 02
1:15pm ET
Moderna’s Hold Rating Maintained Amidst Positive Sales Outlook and Awaited RSV Vaccine Launch
May 02
9:40am ET
Unusually active option classes on open May 2nd
May 02
8:14am ET
MRNA Earnings: Moderna Reports Mixed Results in Q1
May 02
7:47am ET
Metagenomi price target lowered to $17 from $21 at ChardanModerna
May 02
7:05am ET
Options Volatility and Implied Earnings Moves Today, May 02, 2024
May 02
6:39am ET
Moderna: 2024 expectations remain consistent with prior expectations
May 02
6:37am ET
Moderna reaffirms 2024 product sales outlook
May 02
6:36am ET
Moderna sees initial regulatory approvals of RSV vaccine in 1H24
May 02
6:35am ET
Moderna reports Q1 EPS ($3.07), consensus ($3.35)
May 02
5:21am ET
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Moderna (MRNA) and Neurocrine (NBIX)
May 02
4:52am ET
Metagenomi downgraded to Neutral from Overweight at JPMorgan
May 01
8:25pm ET
Notable companies reporting before tomorrow’s open
May 01
1:55pm ET
Notable companies reporting before tomorrow’s open
Apr 30
7:40am ET
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Moderna (MRNA) and Ionis Pharmaceuticals (IONS)
Apr 26
12:45pm ET
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
Apr 26
4:55am ET
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
May 13
7:00am ET
Moderna to Present at Upcoming Conferences in May/June 2024
May 10
7:00am ET
Moderna Announces Update on Investigational RSV Vaccine
May 02
6:30am ET
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Apr 25
7:00am ET
Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
Apr 24
8:00am ET
Moderna and OpenAI Collaborate To Advance mRNA Medicine
Apr 17
7:00am ET
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Apr 03
11:00am ET
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Mar 27
6:30am ET
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Mar 26
7:00am ET
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
MRNA Financials
Key terms
Ad Feedback
MRNA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MRNA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range